TrialJournal of clinical psychopharmacology

Human Abuse Potential of Single Oral Doses of Sunobinop, a Novel, Highly Potent, and Selective Partial Agonist for Nociceptin/Orphanin-FQ Peptide (NOP) Receptors.

Stephen C Harris et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.